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Summary 
Intercellular adhesion molecule-1  (ICAM-1,  CD54)  is a ligand for the integrins lymphocyte 
function  associated-1  (LFA-1,  CD11a/CD18)  and complement receptor-3  (Mac-l,  CD11b/ 
CD 18) making it an important participant in many immune and inflammatory processes. Mod- 
ified recombinant soluble ICAM-1 formed dimers. This result indicated that the ectodomain of 
ICAM-1  contains homophilic  interaction sites.  Soluble  ICAM-1  dimers bind  to solid-phase 
purified LFA-I with high avidity (dissociation constant  [Ka] =  8  nM)  in  contrast to soluble 
ICAM-1 monomers whose binding was not measurable. Cell surface ICAM-1 was found to be 
dimeric based on two distinct criteria. First,  a monoclonal antibody specific for monomeric sol- 
uble ICAM-1, CA7, binds normal ICAM-1 poorly at the cell surface; this antibody, however, 
binds strongly to two mutant forms of [CAM-1 when expressed at the cell surface, thus identi- 
fying elements required  for dimer formation.  Second,  chemical cross-linking of cell surface 
ICAM-1  on  transfected  cells  and  tumor necrosis  factor-activated endothelial  cells  results  in 
conversion of a portion oflCAM-1 to a covalent dimer. Cell surface ICAM-1 dimers are more 
potent ligands for LFA-l-dependent adhesion than ICAM-1 monomers. While many extracel- 
lular matrix-associated ligands of integrins are multimeric, this is the first evidence of specific, 
functionally important homodimerization of a cell surface integrin ligand. 
C 
ell adhesion is a regulated process mediated by specific 
molecular interactions between adhesion receptors (1, 
2). Regulated changes in adhesion are critical in morpho- 
genesis, wound  healing,  the  integrity  of solid  tissues,  and 
host defense (3-5).  Lymphocytes take advantage of an in- 
tersection between two adhesion molecule families, the in- 
tegrin family and the Ig superfamily, to bring cell-cell ad- 
hesion under control of specific immunological recognition 
events  (2).  The  lymphocyte  integrin  LFA-1  responds  to 
lymphocyte activation by increasing its avidity for its three 
known ligands,  intercellular adhesion molecules (ICAMs)1-1, 
-2, and -3, which are members of the Ig superfamily (2, 3). 
While many extracellular matrix ligands for integrins are 
dimers or higher oligomers (6), little is known of the orga- 
nization  of cell  surface  adhesion  molecules  (7-9).  Mem- 
1 Abbreviations used in this paper: BCECF-AM, 2',7'-bis-(2-carboxymeth- 
yl)-5-(and 6)-carboxyfluorescein,  acetomethoxy ester; BS3, bis (sulfosuc- 
cinimidyl) suberate; DSS, disuccinimidyl suberate; GPI, glycosylphos- 
phatidyl inositol; HA. hemagglutinin; HUVEC, human umbilical vein 
endothelial cells; ICAM, intercellular adhesion molecule. 
brane proteins may oligomerize with substantial lateral con- 
tact between molecules (10,  11) or may exist as preformed 
clusters with local concentration but no evidence of direct 
interaction (7). Oligomerization or clustering both may fa- 
vor adhesion  by suppressing  net  dissociation  (12).  How- 
ever, the specific subunit relationships in oligomeric recep- 
tors,  but  absent  in  clusters,  may  uniquely  contribute  to 
ligand-induced  conformational  changes  and  signaling 
events (13,  14). 
ICAM-1 is the most potent ligand for adhesion mediated 
by binding of LFA-1  (15,  16).  While it has been assumed 
that the potency of ICAM-1 as an LFA-1 ligand may be re- 
lated  to  specific properties  of its  unitary  interaction  with 
LFA-1,  it  is  also  possible  that  the  surface presentation  of 
ICAM-1  may have a role in  its effectiveness. Along these 
lines, ICAM-1 has been shown to cluster at one pole of ac- 
tivated T  and B lymphocytes at light microscopy resolution 
(0.6  p.m)  (17-19).  Cell  surface resonance  energy transfer 
with bivalent antibodies suggest that ICAM-1  may self-as- 
sociate and associate with other surface molecules (20,  21). 
However, studies with soluble recombinant ICAM-1 have 
led to the conclusion that ICAM-1 is monomeric (22,  23). 
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been used to evaluate the hypothesis that ICAM-1 is oligo- 
meric at the cell surface. These studies were initiated by the 
observation that  subtle modifications of soluble recombi- 
nant ICAM-I allowed it to form stable noncovalent dimers 
in solution. We conclude that ICAM-1 forms homodimers 
at the cell surface and that the transmembrane domain and 
domain 3 contribute to dimerization. Homodimers formed 
by transmembrane ICAM-1 support greater levels of LFA- 
l-dependent cell adhesion than the monomers formed by a 
chimeric glycolipid-anchored form of ICAM-1. 
Materials and Methods 
Reagents and Enzymes.  Reagents were  obtained from  Sigma 
Chemical Co.,  St.  Louis,  MO,  or  Fisher  Scientific  Co.,  Pitts- 
burgh,  PA,  unless  otherwise  indicated.  FITC goat  anti-mouse 
IgG (H+L)  was acquired from Zymed Laboratories  (South  San 
Francisco,  CA).  Reagents for Western blotting and chemilumi- 
nescent detection of mouse and rabbit antibodies were purchased 
from Amersham Corp.  (Arlington Heights,  IL). Octyl-i3-D-glu- 
copyranoside  and hygromycin B  were purchased  from  Calbio- 
chem Corp.  (La Jolla,  CA).  Lipofectamine and Geneticin were 
purchased  from GIBCO BILL (Gaithersburg,  MD). 2',7'-bis-(2- 
carboxymethyl)-5-(and 6)-carboxyfluorescein,  acetomethoxy es- 
ter  (BCECF-AM)  and  FITC were  purchased  from  Molecular 
Probes,  Inc. (Eugene,  OR.). Disuccinimidyl (DSS) and bis(sulfo- 
succinimidyl)  suberate  (BS3) cross-linkers  were  purchased  from 
Pierce  Chemical  Co.  (iLockford,  IL). Soluble  recombinant 
ICAM-1  purified by  nonaffinity and  immunoaffinity methods 
was a gift of Steven D.  Marlin, Boehringer Ingelheim Pharma- 
ceuticals, Inc. (iLidgebury,  CT). Antiserum reactive with the cy- 
toplasmic  tail  of ICAM-1  was  a gift  of Takashi  K.  Kishimoto, 
Boehringer Ingelheim. 
CellLines  and Antibodies.  The  T  lymphoma  SKW3,  the  B 
lymphoblastoid cell line  JY, the TS2/4 hybridoma were obtained 
from  T.  Springer  (Center for  Blood  ILesearch,  Boston,  MA). 
TS1/22, TS1/18, and TS2/18 hybridomas and COS 1 cells were 
from American Type Culture Collection, ILockville, MD. BHK 
VP16 cells were generated at Monsanto Chemical Co., St. Louis, 
MO.  (24). Human umbilical vein endothelial cells (HUVEC) 
were purchased from Clonetics Corp. (San Diego, CA). HUVEC 
were treated  with 10 ng/ml TNF (Collaborative  ILesearch, Lex- 
ington, MA) before use in flow microfluorimetry and cross-link- 
ing experiments.  CL203  ascites was a gift of S. Ferrone (Upstate 
Medical  College,  Valhalla, NY). Purified NKI-L16 was a gift of 
C. Figdor (University Hospital, Nijmegen, The Netherlands).  Pu- 
rified  1KIL1/I was a gift of R.  ILothlein (Boehringer  lngelheim 
Pharmaceuticals, Inc.). M174F5B7, M178A7A1, and M261PP5C7 
were generated and characterized at Monsanto Chemical Co. (24). 
Affinity-purified rabbit anti-ICAM-1 ectodomain and a  crude 
antiserum against the ICAM-1 cytoplasmic tail were prepared  by 
injecting  rabbits with soluble recombinant ICAM-1 (25). 
DNA Constructs and Expression of Recombinant Proteins.  BHK- 
VP16  cells expressing  ICAM-1  with a hemagglutinin tag were 
grown in DME  10% FCS, 453 U/ml hygromycin, and 200 btg/ 
ml  of G418.  Soluble  ICAM-1  was  produced  in a  cell  factory 
(Nunc,  ILoskilde,  Denmark)  and  purified  by  immunoaffinity 
chromatography on M174F5B7 Affiget with  elution at  pH  3.0 
and immediate neutralization (24). Sequencing of ICAM-1-HA 
revealed  an Arg to Trp conversion at residue  361  (IL361W) in 
domain 4 which is probably a PCR artifact. This mutation does 
not affect interaction with LFA-1 but we cannot rule out that this 
change  has a role  in stable dimer formation. Plasmids encoding 
full-length transmembrane ICAM-1  (26), glycosylphosphatidyl 
inositol (GPI)-anchored ICAM-1  (27), and ICAM-1, with re- 
moval of domain 3, domain 5, or the cytoplasmic tail (22) in the 
vector  CDM8,  were  obtained  from  T.  Springer  (Center  for 
Blood  Research).  Constructs  in  CDM8  were  transfected  into 
COS cells by the DEAE-Dextran method (28) and analyzed be- 
tween 24 and 72 h  after transfection.  The full-length ICAM-I 
and GPI-anchored ICAM-1 cDNA were subcloned into the vec- 
tor 3360B  (24) and transfected  into BHK-VP16 cells with lipo- 
fectamine to  produce stable  cell  lines  expressing  high levels of 
transmembrane and GPI-anchored ICAM-1. 
Protein Iodination.  Soluble ICAM-1 was iodinated with 1,3,4,6- 
tetrachloro-3cx,6&-diphenylglycouril (29). 30  ~zg of ICAM-1  was 
iodinated with 1 mCi of NalZSI and separated from free iodine on 
Sephadex  G-25. mAbs were similarly iodinated with 1 mCi/100 
p,g protein. 
Solid-Phase Receptor  Binding Assays.  Immunoaffinity  purified 
LFA-1  (18) was adsorbed  to polystyrene as previously described 
(30). Briefly, LFA-1  in 1% ocwlglucoside detergent was diluted 
into 9 vol PBS/2 toNI MgC12 in wells of an untreated microtiter 
plate  (Nunc; Coming Glass Inc., Coming, NY; or ICN/Flow, 
Costa Mesa, CA) and incubated for 1 h at room temperature with 
gentle agitation (microplate  shaker set at 4-5; Bellco Biotechnol- 
ogy,  Vineland, NJ).  The  solution was  aspirated  and the  plates 
were blocked with  1% heat-treated BSA in PBS/2 mM MgC12 
plus 0.02% NAN3. Heat-treated BSA solutions were prepared  by 
bringing a 1% BSA solution in PBS/2 mM MgCI2 to 80~  in a 
microwave oven followed by rapid cooling to room temperature 
and 0.2-p~m filtration.  After blocking with the heat treated  BSA 
for at least 1 h at room temperature the plates were washed with 
PBS/2 mM MgC12 and stored  in this solution until use.  These 
plates were rinsed with assay buffer (PBS, pH 7.4, 5% fetal bovine 
serum,  2 mM MgCI  2, and 0.02% NAN3) before  adding iodinated 
ICAM-1 for the indicated time at 4~  The plates were rapidly 
washed four times and the bound radioactivity  was released with 
sequential  1  N  NaOH  and  1  N  acetic  acid  washes  that  were 
pooled for gamma counting. 
ImmunoradiometricAssays.  The capture antibody was adsorbed 
to Nunc Maxisorb plates (Nunc) at 25 o,g/ml in PBS overnight. 
After  blocking with heat-treated BSA as above the plates were 
washed  with assay medium and the samples containing purified 
proteins were added  and incubated for at least 1 h at 4~  The 
plates were then washed  three times with assay medium and the 
iodinated detection reagent was added in excess and incubated at 
least 1 h at 4~  The plates were then washed four times with as- 
say medium and the  bound radioactivity  was  eluted with  1 N 
NaOH  then  1 N  acetic  acid  as above.  If the sample  contained 
membrane proteins then assay medium was substituted with 25 
mM  Tris,  pH  8.0,  I%  Triton X-100,  0.15  M  NaC1, and the 
plates were blocked again with heat-treated BSA before addition 
of the iodinated detection antibody in assay media. 
Gel Filtration and Sedimentation.  Gel filtration  was perfomaed 
on a fast perfbrmance liquid chromatography system (Pharmacia 
LKB Biotechnology, Piscataway, NJ) using the indicated columns. 
Sedimentation through 5-20% sucrose gradients was used to de- 
termine the sedimentation coefficient by interpolation from stan- 
dard proteins.  Data from gel filtration, sedimentation, and the es- 
timated partial specific volume were used to calculate molecular 
weights using the Svedberg equation: tool wt =  (6"rr'q2o,,,NaS2,.,,.)/ 
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Avogadro's number, a is the Stoke's radius, S20,w is the sedimenta- 
tion coefficient corrected to water at 20~  v is the partial specific 
volume, and P20.w is the density of water at 20~  (31, 32).  The 
columns and sucrose  gradients  were calibrated  for measurement 
of Stoke's radius and sedimentation coefficient  using ovalbumin 
(43 kD, 2.76 nm, 3.5 S), BSA (66 kD, 3.70 nm, 4.5 S), aldolase 
(150 kD, 4.74 nm, 7.6 S), catalase (200 kD, 5.22 nm, 11.2 S), and 
ferritin (430 kD, 6.1 nm) (31, 33). 
Flow Cytometry.  Monodispersed suspension of adherent cells 
was  obtained by treatment of cell  layers  with  HBSS  with  no 
CaC12 or MgC12 and 0.5 mM EDTA. Suspension cells were taken 
from log phase cultures.  The cells were washed with HBSS plus 
5% FBS, 0.5 mM EDTA, 0.02% NaN  3 (staining media).  106 cells 
were incubated in 50 gtl of staining medium plus the primary an- 
tibody for 60 rain at 4~  and then washed  two times.  The sec- 
ondary antibody was then added at 10 Ixg/ml in 50 p,1 of staining 
medium, incubated an additional 30  rain at  4~  and the  cells 
were washed twice. The stained cells were analyzed within 12 h 
on a FACScan  |  (Becton Dickinson and Co., Mountain View, CA). 
Chemical Cross-Linking.  Soluble ICAM-1 was cross-linked at 
room temperature in PBS, pH 7.4, with the indicated concentra- 
tions of DSS dissolved in DMSO. The cross-linking was allowed 
to  proceed  for  30  min before  addition of excess glycine.  The 
samples were then subjected to reducing SDS-PAGE. Cell sur- 
face  cross-linking was performed on ice  with all reagents  pre- 
chilled. In some experiments cells were first iodinated by the glu- 
cose-oxidase-coupled lactoperoxidase  method  using  1, mCi  of 
125I/2 ￿  107 cells (34, 35). Cells (105-106) in 100 btl of cold PBS, 
pH  7.4,  were  treated with the  indicated concentration of BS3, 
dissolved immediately before use in 150 mM NaC1, 0.1 mM HC1 
at 100 mM, for 30 man followed by blocking with excess glycine 
and simultaneous treatment with  5  mM  iodoacetamide for  10 
rain on ice  to  alkylate  free  sulfhydryl  groups  within the  intact 
cells. The cells were then pelleted and resuspended in 0.5  ml of 
lysis buffer (25  mM  Tris,  pH  8.0,  1%  Triton X-100,  0.15  M 
NaC1, 5 mM EDTA, 5 mM iodoacetamide,  1 mM PMSF, and 50 
millitrypsin  inhibitor units of aprotinin) and sonicated for 10 s at a 
setting of 1 with a microtip probe sonicator on ice (sonifier 450; 
Branson Ultrasonics Corp.,  Danbury,  CT).  The  sonicate  was 
centrifuged at 30,000 g for 15 rain and the supernatant was pro- 
cessed by immunoprecipitation, SDS-PAGE, and autoradiogra- 
phy, or by SDS-PAGE and Western blotting. 
Immunoprecipitation,  The  cleared  lysate was  incubated over- 
night at 4~  with 25 gel of irrelevant antibody Sepharose CL-4B 
to remove nonspecifically binding components. The supernatant 
was  then incubated with 25  gtl  of specific antibody Sepharose 
CL-4B  (a mixture of KtL1/1, CL203,  and M174 for ICAM-I) 
for 2 h at 4~  After this incubation the supernatant was removed 
and the beads  were  washed  extensively,  heated to  100~  with 
SDS-PAGE  sample  buffer,  and  subjected  to  reducing  SDS- 
PAGE. The gels were dried and subjected to film autoradiogra- 
phy with an intensifying  screen. 
Western Blotting.  The cleared lysate was mixed with 50 gtl of 
wheat germ agglutinin agarose (EY Laboratories, San Mateo, CA) 
for 1 h at 4~  followed by washing of the resin twice with lysis 
buffer followed by one wash  with  10  mM  Tris,  pH  7.5.  The 
washed  wheat germ agglutinin agarose was treated  with nonre- 
ducing SDS-PAGE sample buffer (including 50 mM iodoaceta- 
mide)  at 100~  for 5 rain and the soluble fraction was subjected 
to  SDS-8%-PAGE. The  glycoproteins were  electrophoretically 
transferred  to nitrocellulose,  blocked with 5% nonfat dry milk in 
PBS 0.1% Tween-20, and incubated with the indicated primary 
antibodies which were detected by secondary horseradish peroxi- 
dase antibodies and enhanced chemiluminescence  on x-ray film. 
Cell Adhesion Assays.  JY  cells were fluorescently labeled us- 
ing a  solution of 5  txM BCECF-AM in RPMI-1640 medium 
plus 2% fetal bovine serum for up to 2 ￿  107 cells in 5 ml. The 
cells were incubated with BCECF-AM for 45 mAn in a 37~  in a 
5% CO  2 incubator with periodic agitation after which they were 
washed four times with assay medium (RPMI-1640 10% fetal bo- 
vine serum, 5 mM Hepes, pH 7.4). The cells to be used as targets 
were plated in 96-well plates at 5  ￿  103-104 cells/well and al- 
lowed  to  grow  to  2-4  ￿  104  cell/well.  The  cell  layers  were 
washed twice with assay media before adding blocking antibodies 
at 10 p,g/ml. 105 BCECF-labeled cells were added in 50 Ixl of as- 
say medium and the plates  were  centrifuged 5  rain at  10 g  to 
bring the BCECF-labeled cells into contact with the monolayer. 
The plates were then read  quickly on a microplate fluorimeter 
(Cytofluor 2300; Millipore, Marlborough, MA) to determine the 
fluorescence  level  from each  well.  This required ~1  rain. The 
plates were then incubated for 15 rain at 37~  by flotation in a 
37~  water bath and then washed  four times  with prewarmed 
medium using a 12-channel vacuum manifold (Drummond Sci- 
entific Co., Broomall, PA) operating at 25 inches of rig vacuum. 
Between washes medium was added down the sides of the wells 
with a 12- or 8-channel pipettor. The assay medium was replaced 
and the plates were read on the microplate fluorimeter. Percent 
cell binding was determined on a well-for-well basis as the [(final 
reading -  media blank)/(prewash reading -  media blank)]  X 
100. All points were determined in quadruplicate  with averaging 
after determination of percentage of cells bound. 
Results 
Hemagglutinin-tagged ICAM-1 Forms Oligomers.  Soluble re- 
combinant ICAM-1 generated by introducing a stop codon 
before  the  beginning of the  transmembrane domain  re- 
mains monomeric in solution even when concentrated to 
>20 mg/ml (22, 23)  (Fig. 1 A). We were surprised to find 
that addition of a commonly used influenza hemagglutinin- 
derived epitope tag to  the  COOH-terminus of truncated 
soluble ICAM-1 (ICAM-1-HA) led to the ability of a sig- 
nificant proportion of ICAM-1-HA to  form stable oligo- 
mers when concentrated to  15  mg/ml as indicated by gel 
filtration and sedimentation. Gel filtration resolved ICAM- 
1-HA into two  peaks  with apparent Stoke's radii of 5.22 
and 6.14 nm (Fig.  1 A). Unmodified soluble recombinant 
ICAM-1 had an apparent Stoke's radius of 5.16 nm. These 
two peaks were then individually  subjected to velocity sed- 
imentation on 5-20% sucrose gradients. The smaller species 
sedimented in a sucrose gradient at 3.7  S while the larger 
sedimented at 5.45 S (Fig. 1 B). ICAM-1-HA has a mass of 
67  kD  by mass spectroscopy  (Carron,  C.  P.,  unpublished 
observation). The partial specific volume (0.72  ml/g) was 
estimated from a polypeptide molecular mass of 51  kD and 
carbohydrate mass of 16 kD and the Svedberg equation was 
used to determine molecular masses of 79 and 147 kD for 
the  small  and  large  species,  respectively  (31).  The  large 
Stoke's radii are consistent with a rod-like shape oflCAM-1 
(22,  36).  These data show that ICAM-1-HA forms stable 
dimers with no higher oligomers, suggesting a specific in- 
teraction. 
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Figure  1.  Dimerization of ICAM-1-HA. (A) slCAM-1 (squares) and 
ICAM-1-HA (circles)  diluted from stocks of 22 and 15 mg/ml, respec- 
tively, were immediately  iodinated and subjected to gel filtration  on a 2.5 
￿  50-cm  Superose 6 column run at 0.4 ml/min. 1-ml  fractions  were col- 
lected and analyzed for 12sI. All counts represented ICAM-1 based on 
ability to adsorb them to microtiter plate wells coated with CL203 (not 
shown). (B) Fraction 61  (diamonds) and 70 (triangles)  from ICAM-1-HA 
gel filtration  in A were sedimented  on 5-20% sucrose gradients  for 24 h at 
38,000 rpm in an SW41 rotor (Beckman Instruments,  Inc.). The gradi- 
ents were fractionated  from the top using a Gradifrac (Brinkmann  Instru- 
ments, Inc.) and 48 fractions  were collected into a microtiter plate. Stan- 
dards were run in parallel. 
Additional evidence  for  dimerization  of ICAM-1-HA 
was  obtained  by  chemical  cross-linking.  The  small  and 
large  ICAM-1  species isolated by gel filtration were  sub- 
jected to cross-linking  with DSS and the results analyzed by 
reducing SDS-PAGE.  Cross-linking over a  range of DSS 
concentrations had  no effect on migration of the  ICAM- 
1-HA  from  fraction  70,  but  converted  about  half  of 
ICAM-1-HA from fraction 61 to a doublet of 190 and 210 
kD  (Fig.  2).  The  two  high  molecular weight  species  are 
most likely representative of two cross-linking isomers of a 
single dimer.  The  doublet may  result from  formation of 
covalent  bonds  at  two  different  points  along  the  two 
ICAM-1  polypeptides.  For  example,  one isomer may be 
cross-linked end  to  end,  while  the  other  may  be  cross- 
linked  in  the  middle  of  the  polypeptides  to  yield  an 
X-shaped form that would migrate faster. 
The  HA  tag  itself has  not  been  reported  to  induce 
Figure  2.  ICAM-1-HA dimers demonstrated by chemical cross-link- 
ing. Fractions  61 and 70 from Fig. 1 A were diluted in PBS and treated 
with DSS at the indicated  millimolar  concentration.  After 30 rain at room 
temperature the reaction was terminated  by adding excess glycine  and the 
samples were subjected  to reducing SDS-6%-PAGE  and autoradiography. 
The decrease in intensity of the fraction 70 bands with increasing  cross- 
hnker was not always observed and may be due to increased  hydropho- 
bicity of DSS-modified, nondimeric  ICAM-1-HA. 
dimerization of nonoligomeric proteins.  A  secreted  mo- 
lecule in which  ICAM-1  domains 1  and 2  are  followed 
by the same HA tag was monomeric at an even higher mo- 
lar  concentration than  used  to  drive  dimerization of the 
5-domain ICAM-1-HA (data not shown).  Thus it would 
appear that ICAM-1 domains 3-5 contain homophilic in- 
teraction sites that work  in parallel with the  HA-derived 
peptide sequence to form stable dimers.  It is possible that 
the R361W mutation in domain 4  may contribute to the 
stability to the dimer. This mutation, however, is unlikely 
to have this effect unless there is a predisposition oflCAM-1 
ectodomains to interact. 
ICAM-1-HA  Dimers  Bind  to  Purified  LFA-1  with  High 
Avidity.  Does ICAM-1 dimerization lead to an enhanced 
avidity  for  LFA-I?  LFA-1  exists  in  at  least  two  avidity 
states,  low  on resting lymphocytes and high  on activated 
lymphocytes.  However,  even  on  activated  cells,  only  a 
small  fraction  of LFA-1  molecules may  be  able  to  bind 
ICAM-1  (37).  Immunoaffinity-purified  LFA-1  provides a 
homogeneous source of high avidity LFA-1 (30). Iodinated 
ICAM-1-HA resolved into dimer- and monomer-enriched 
fractions by gel filtration (Fig.  1 A) was tested for binding 
to  immunoaffinity-purified LFA-1  adsorbed  to  plastic.  A 
peak of stable LFA-1 binding corresponding to the peak of 
ICAM-1-HA dimer was  observed, while no binding was 
detected corresponding to the peak oflCAM-1-HA mono- 
mer.  ICAM-1-HA dimer binding to  immobilized LFA-1 
displayed  a  two-component binding curve,  suggesting  a 
small number of high affinity binding sites that were satu- 
rated at the highest concentrations of ICAM-1-HA and a 
larger number of low affinity sites that were not saturated at 
the  highest  concentrations attainable  in  our  experiments 
(Fig.  3  B).  ICAM-1-HA dimer binding reached  equilib- 
rium after 1 h at 4~  with gentle agitation and displayed re- 
versibility (not shown) suggesting that equilibrium binding 
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Figure 3.  Binding of ICAM-I-HA dimers to immunoaffinity-purified 
LFA-1- A. ICAM-1-HA at 15 mg/ml was fractionated on a Superose 6 
column as in Fig. 1 and the fractions were tested for binding to immu- 
noaffinity-purified  LFA-1 adsorbed to polystyrene by coincubation for 60 
man at 4~  followed by four washes over a 2-3-min period. Remaining 
counts were  determined  (solid line with circles) and plotted  against total 
counts (dashed line). (t3) Dependence of ICAM-1-HA dimer binding to 
immunoaffinity-purified LFA-1 on  ICAM-1-HA concentration.  The 
data from the filled squares was replotted in the inset by the method of 
Scatchard (38) focusing on  the  high  affinity class of binding sites for 
which near saturation is obtained. 
analysis may be used to obtain an affinity. Scatchard analysis 
clearly demonstrated a high affinity component with a dis- 
sociation constant [K~ of 8 nM (Fig. 3 B, inset). The maxi- 
mum binding level for the high affinity sites corresponds to 
10% of the LFA-1 sites detectable with iodinated antibodies 
to LFA-1  (not shown).  This high affinity interaction sug- 
gests  that  dimeric  ICAM-1  is  functionally  distinct  from 
monomeric  ICAM-1  and  led  us  to  examine  cell  surface 
ICAM-1 for oligomerization. 
An  mAb  Selective for  ICAM-1  Monomers  Does  Not  Bind 
Cell Su~ce ICAM-1.  The availability of the ICAM-1-HA 
dimers led us to  test a  panel of ICAM-1  mAbs for oligo- 
merization-sensitive binding. Such an antibody could then 
be  used  to  distinguish  between  ICAM-1  monomers  and 
dimers  at  the  cell surface.  The  mAb  CA7  (Fig.  4,  &des) 
bound  monomeric  ICAM-1  equally to  our  reference  re- 
agent  CL203  (Fig.  4,  squares)  but  bound  dimeric  ICAM- 
1-HA weakly. This monomer-specific antibody CA7 binds 
to the fifth Ig-like domain (23), whereas the other ICAM-1 
mAbs,  1<IL1/1,  1<6.5,  and  CL203  bind  to  domains  1,  2, 
and 4,  respectively. Two  other mAbs to domain 5,  M178 
and  M261PP5C7,  bound  both  monomeric  and  dimeric 
ICAM-1 HA similarly to CL203  (not shown). 
We  analyzed  a  number  of  cells  expressing  natural 
ICAM-1,  including JY  B  lymphoblastoid cells  (Fig.  5  A 
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Figure 4.  CA7 binds ICAM-1-HA monomer but not dimer. ICAM- 
1-HA 15 mg/ml (A) or slCAM-1 22 mg/ml (B) fractions from Superdex 
200  column  chromatography were  tested for binding  to  immobihzed 
CL203 (squares) or CA7 (&des). Binding of soluble ICAM-1 was detected 
with 12SI-R.P,1/l. The small amount of CA7 binding in dimer fraction is 
probably due to dissociation  of dimers since the size of this peak increased 
progressively  with storage of the column fractions (not shown). 
and  Table  1),  U937  premonocytic  leukemia  cells,  three 
melanoma  cell  lines,  and  TNF-treated  HUVEC  (not 
shown), for binding of CA7 to ICAM-1  on live cells. We 
were surprised to find that the level of CA7 binding is <5- 
10%  of binding  of other  ICAM-1  antibodies,  including 
R1<1/1  or CL203.  In contrast, M261PP5C7  (Table 1) and 
M178  (not shown)  bind ICAM-1  at the cell surface simi- 
larly to 1<1<1/1  and  CL203  (Table  1).  Thus,  most  of the 
natural  ICAM-1  at  the  cell surface appears  dimeric based 
on CA7 binding. 
Binding of CA7  to BHK cells expressing ICAM-1  mu- 
tants  was  tested  to  examine  structural  requirements  for 
ICAM-1  dimerization.  Replacement  of ICAM-ls  trans- 
membrane  and cytoplasmic tail through addition of a  GPI 
anchor (27) resulted in binding of CA7 at a level similar to 
R1<1/1  (Fig.  5  C;  compare  5  B,  Table  1).  In  contrast, 
ICAM-1  with  all but two  residues of the  cytoplasmic tail 
deleted  bound  CA7  similarly to  full-length  ICAM-1,  at 
<5% the level of R.1<1/1  (not shown). Together, these re- 
sults  implicate  the  transmembrane  domain  in  ICAM-1 
dimerization. 
Deletion of domain 3  increased binding of CA7 relative 
to  other  ICAM-1  antibodies  (Table  1).  Therefore,  high 
binding of CA7  can  occur in  a  transmembrane-anchored 
form  of ICAM-1  on live cells and  domain 3  may also be 
involved  in  contacts  leading  to  stabilization of ICAM-1 
dimers. 
1235  Miller et al. Table  1.  Immunofluorescence  Detection of lCAM-1  Epitopes 
Ratio 
Cell line  TS2/18  RR1/1  CL203  CA7  M261  CA7  +  RR1/1 
JY  1.7  141  120  12  71  0.074 
BHK ICAM-1.4  8.1  2,590  3,070  371  2,250  0.14 
BHK GPI-ICAM-1.11  14.3  1,790  1,820  1,340  1,670  0.74 
BHK ICAM-I D3-  8.0  359  83  217  177  0.59 
BHK ICAM-I D5  7.5  1,160  1,270  9.5  16  0.002 
JY cells or stable BHK cell lines were stained with the indicated mAb at 10 ug/ml for 60 min at 4~  and then with 50 lig/ml FITC goat anti-mouse 
lgG. TS2/18 is an lgG1 mAb to human CD2 which is used as a negative control. Data are reported as the mean linear fluorescence in arbitrary but 
internally  consistent units. The last column shows the ratio of specific CA7 staining to 1<P,1/1 specific staining (TS2/18 background subtracted). In- 
creasing primary antibody concentrations to 100 p,g/rnl and staining at 37~  for 30 min did not significantly increase CA7 staining  relative to RR.1/ 
1. The staining pattern of  JY cells for 1<1<1/1 and CA7 is representative  of staining of cell lines and primary cells that naturally express ICA/VI-1. A 
second new antibody to domain 5, M178A7A1,  gave similar results to M261PP5C7. 
ICAM- 1 Cross-Linking  at the Cell Surface Identifies ICAM- 1 
Dimers.  Chemical  cross-linking  was  used  to  analyze 
ICAM-1 neighbors on stably or transiently transfected cells. 
ICAM-1  epitopes  are  sensitive  to  chemical  modification 
of lysines  which  are  required  for  chemical  cross-linking 
(Miller, J.  M.  and M.  L. Dustin, unpublished observations) 
so a  strategy was adopted  in which covalent modifications 
were  restricted  to  the  ectodomain  of ICAM-1  by using a 
non-membrane permeant cross-linker (BS3) on intact cells, 
and an  antibody to  the  cytoplasmic  tail was  then  used  to 
detect  ICAM-1  on Western blots.  Cross-linking was  per- 
formed at 4~  since this has been shown to enhance speci- 
ficity  for  cross-linking of oligomeric  membrane  proteins 
(39).  To reduce nonspecific bands obtained with the anti- 
cytoplasmic  tail  antibody,  glycoproteins  were  isolated  on 
;'  /":. 
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wheat  germ  agglutinin  agarose  before  SDS-PAGE  and 
Western blotting. In the absence of cross-linking, a  diffuse 
80-90-kD  band  typical  of ICAM-1  on  nonreduced  gels 
was  observed  specifically in ICAM-l-transfected  cells but 
not mock-transfected cells (Fig. 6).  Addition of BS3 at 4~ 
resulted in a  shift of a  portion of the immunoreactive 80- 
90-kD ICAM-1 to a  190-kD band (Fig. 6, and Fig. 7, lanes 
4-6).  The proportion of ICAM-1 cross-linked under opti- 
mal conditions was ~20%.  When similar experiments were 
performed with tran-siendy transfected COS  cells, virtually 
all of the 80-90-kD ICAM-1  shifted to  190 kD after cross- 
linking with  1  or  5  mMBS  3  (Fig.  7,  lanes  I-3).  In both 
BHK cells and COS cells a single band was observed. 
The  hypothesis  that  ICAM-1  forms  dimers  at  the  cell 
surface was further tested  in TNF-treated HUVEC  which 
naturally express levels of ICAM-1  comparable to those in 
the  ICAM-l-transfected  BHK  cells  (Fig.  7,  lanes  7-9). 
The overall efficiency of ICAM-1  conversion to high mo- 
lecular weight  species  in HUVEC  was  similar to  that  ob- 
served in BHK  cells.  However,  in addition to  the  distinct 
band  corresponding  to  dimeric  ICAM-1,  as  observed  in 
COS  and BHK  cells, a lower relative molecular mass band 
g 
~] B,I  )~  Figure 5.  Differential IC~-1 
n  ~  epitope  expression  on  normal 
=  t  ~  !  !  ~s  cells  and  ICAM-1  transfected 
Z  "~  cells.  Binding of mouse  mAbs 
Q  TS2/18  (negative control,  solid) 
0  e~  .~.,:  e:,...  . ..~7.  ILK1/1  (dotted), CA7  (stippled), 
1  10  10  2  103  104  and  M261PPSC7  (dashed) was 
determined  by subsequent bind- 
~] C  ing  of  FITC  goat  anti-mouse 
1~  i!'!;  lgG  and fl~  micr~176 
on a FACScan  |  (Becton Dickin- 
o  son and Co.).  Cells tested were 
t/  L_g  \.  BHK-VPI6  cells  transfected 
1  lo  lo  2  1  0  3  lo  4  with  transmembrane  ICAM-1; 
and (C)  BHK-VP16  cells trans- 
Fluorescence intensity  fected with GPI-ICAM-I. 
Figure 6.  Chemical  cross-linking of ICAM-1 at the surface of BHK 
(-VP16) and BHK-(VP16-)ICAM-1.  Cells were incubated with the indi- 
cated concentration of BS  3 at 4~  and processed for nonreducing SDS- 
8%-PAGE as described in Materials and Methods. ICAM-I was detected 
with an antibody to the cytoplasmic tail. 
1236  Intercellular Adhesion Molecule-1 Dimers Figure 7.  Chemical cross-linking of ICAM-1  at the surface of COS 
cells (lanes I-3), BHK cells (lanes 4-6), and TNF-treated HUVEC  (lanes 
7-9). HUVEC were treated with 10 ng/ml TNF for 24 h. ICAM-1 was 
detected with  anti-cytoplasmic tail antiserum after cross-linking at the 
cell surface with the indicated concentration ofBS  3 at 4~ 
corresponding  to  about  one-third  of the  high  molecular 
weight ICAM-1 was also detected in HUVEC. 
The possibility that ICAM-1 may form heterodimers on 
the surface of endothelial cells was further evaluated by sur- 
face  iodination,  cross-linking,  and  immunoprecipitation 
with a  cocktail of anti-ICAM-1 mAbs. A  different pattern 
was  obtained  with  TNF-treated  HUVEC  or  BHK  cells 
expressing transmembrane  ICAM-1  (Fig.  8).  After  cross- 
linking with  an  optimal  concentration  of BS3,  the  most 
prominent bands on reducing SDS-8%-PAGE of iodinated 
proteins  immunoprecipitated  from  ICAM-l-transfected 
BHK  cells  are  the  90-kD  monomer,  the  220-kD  dimer, 
and  a  higher  molecular weight  smear  that  may  represent 
higher order oligomers formed due to ICAM-1  clustering. 
ICAM-1  immunoprecipitated  from  cross-linked,  TNF- 
treated  HUVEC  was  distributed  between  several  fainter 
bands,  including  the  220-kD  dimer  band  and  higher 
weight  smear,  but  also including bands  of 186,  160,  130, 
and a  prominent  band  of 106  kD.  The  186-kD  band ap- 
pears to correspond to the additional band in Fig. 7, lanes 8 
and 9.  All of the additional bands were confirmed to con- 
tain  ICAM-1  by  Western  blotting  with  anti-ICAM-1 
ectodomain  antibodies which  are  more  sensitive than  the 
anti-cytoplasmic tail antibodies (not shown).  These  results 
confirm that ICAM-1  homodimers  exist on  cells natural- 
ly  expressing  ICAM-1  and  suggest  that  ICAM-1  het- 
erodimers exist on endothelial cells. It is unlikely that these 
additional bands  arise by proteolysis or  nonspecific  cross- 
linking to  transiently encountered  glycoproteins since the 
same  methods  applied  to  BHK  and  COS  cells  show 
predominantly  only  the  monomeric  and  homodimeric 
ICAM-1 species. 
When  the  cross-linking results  are  considered  together 
with  the  observation that  ICAM-1-HA  forms  dimers  and 
that  expression of a  monomer-selective epitope on  trans- 
membrane ICAM-1 is low at the cell surface, the evidence 
that ICAM-1 can form dimers at the cell surface is compel- 
ling. On a  cell naturally expressing ICAM-1, ICAM-1  ex- 
ists  primarily  as  a  homodimer  but  may  also  form  het- 
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Figure 8.  Chemical cross-linking of ICAM-1  at the surface of iodi- 
hated HUVEC  and BHK  cells. HUVEC were  treated with  10  ng/ml 
TNF for 24 h. TNF-treated HUVEC  and BHK cells were released from 
plates with HBSS/EDTA. Surface iodination and cross-linking were per- 
formed sequentially  as rapidly as possible with cross-linking  performed on 
ice. Immunoprecipitation was performed with a cocktail oflCAM-1 anti- 
bodies and the  immunoprecipitates were  run  on  SDS-8%-PAGE. (A) 
HUVEC  (lanes I and 2) or normal ICAM-l-transfected  BHK cells (lanes 
3 and 4) without (lanes I and 3) and with (lanes 2 and 4) 1 mMBS  3. (B) 
Densitometry  (personal densitometer; Molecular Dynamics, Sunnyvale, 
CA) on lane 2 with arrows pointing to bands and percentage of total op- 
tical density in the region under each band indicated. 
erodimers with other molecules based on the appearance of 
a distinct cross-linked band. 
Role of lCAM-1  Dimer in Cell Adhesion.  It  has  been 
shown that GPI-ICAM-l-transfected COS cells adhere ef- 
ficiently  to  surfaces  coated  with  immunoaffinity-purified 
LFA-1 but no reports of lymphocyte adhesion to  cells ex- 
pressing  GPI-ICAM-1  have  been  published.  Transmem- 
brane  ICAM-1  is dimeric based on  several criteria, while 
GPI-ICAM-1 is monomer-like, based on CA7 epitope ex- 
pression.  The  effect  of ICAM-1  dimerization on LFA-1- 
dependent cell adhesion was tested by examining adhesion 
ofJY B  lymphoblastoid cells to BHK cells stably expressing 
ICAM-1  or GPI-ICAM-1 at similar levels (Table 2).  The 
expression levels were similar by flow cytornetry after stain- 
ing with RRA/1  and by radiometric assays with R1L1/1  or 
CL203. JY cells were used because they are relatively defi- 
cient in [31 integrin family adhesion receptor activity which 
might  increase  the  background  binding  to  fibroblastoid 
cells (40,  41). JY  cells showed twofold greater adhesion to 
the  ICAM-1  than  to  GPI-ICAM-1 stably expressed at the 
same level in BHK cells and this pattern was retained when 
the JY cells were activated with NKI-L16 at 5  Ixg/ml (42). 
The  adhesion  was  inhibited  by  LFA-1  mAb  (Table  2). 
Thus,  the dimeric presentation oftransmembrane ICAM-1 
is more effective in mediating LFA-l-dependent adhesion 
than the monomer-like presentation of GPI-ICAM-1. Table 2.  JY Cell Adhesion to BHK Cells Expressing D!fferent ICAM- I forms 
Antibody  BHK-VP16  BHK-VP16-ICA/VI-1  BHK-VP16-GPI-ICAM-1  A 
T82/18  6.8 •  1.4  21.2 •  1.9 (14.4)  12.6  +  1.7 (5.8)  2.1 
TS1/22  4.2 •  0.7  2.3 _+ 0.6 (-1.9)  2.2 •  0.8 (-2.0)  -- 
NKI-L16  7.9 +  2.0  39.6  _+ 6.5 (31.7)  26.1  •  4.1 (18.2)  1.7 
Data are based on a single experiment in which JY cells were incubated with BHK cell monolayers for 15 rain at 37~  then washed with warm me- 
dia. Specific adhesion is obtained by subtracting adhesion to the mock-transfected BHK cells  from the adhesion to ICAM-l-transfected BHK cells 
and is shown in parentheses. The fold difference between  the BHK-VP16-ICAM-1 and BHK-VP16-GPI-ICAM-1 was calculated by taking the 
specific binding in the presence ofTS2/18 or NKI-L16 and subtracting the specific binding in the presence ofTS1/22 and taking the ratio of these 
numbers for the two BHK cell types which are reported in the column "A." The experiment is representative of four other experiments performed 
with the same conditions. 
Discussion 
ICAM-1  is  the  most  potent ligand for LFA-1  (15,  21, 
26). The molecular basis of the greater avidity of LFA-1 for 
ICAM-1  compared with ICAM-2 or ICAM-3 has been a 
matter  of speculation  since  it  has  not  been  possible  to 
directly  measure  ICAM  interaction  with  LFA-1  except 
through highly multivalent adhesive interactions. We have 
found that  ICAM-1  forms homodimers at the cell surface 
and have investigated the impact of dimer formation on ad- 
hesion.  Soluble  ICAM-1  dimers  bind  stably  to  purified 
LFA-1,  a  property  not  previously  observed  with  other 
forms of ICAM-1, suggesting that the dimers have  an ad- 
vantage in binding to LFA-1. Increased binding of soluble 
ICAM-1 dimers is also reflected in greater adhesion oflym- 
phoblasts  to  cells  expressing  ICAM-1  dimers  rather  than 
ICAM-1 monomers. Greater activity oflCAM-1  dimers in 
cell  adhesion  may  result  from  suppression  of dissociation 
(43) or by more effective triggering ofligand induced con- 
formational changes (13,  44).  ICAM-2 does not cross-link 
with BS  3 suggesting that one of the reasons that ICAM-2 is 
a  less potent  ligand for  LFA-1  than  ICAM-1  is  that  it is 
monomeric  while  ICAM-1  is  dimeric  at  the  cell  surface 
(Dustin, M. L., unpublished observations). ICAM-3 is very 
similar in overall structure to ICAM-1 so it will be of inter- 
est to evaluate whether it can form homodimers. Endothe- 
lial cells appear to express ICAM-1 heterodimers in parallel 
with homodimers, however, establishing the significance of 
this finding will require the generation of reagents to purify 
these putative heterodimers and assess their function  rela- 
tive  to  ICAM-1  homodimers  and  monomers.  The  most 
important contribution of the current studies is the demon- 
stration that ICAM-1 forms homodimers at the cell surface 
and  that  these  homodimers  are  more  potent  than  mono- 
mer-like ICAM-1 forms generated by glycolipid anchoring. 
An important tool in this study was an oligomerization- 
sensitive  antibody,  CA7,  which  recognizes  an  epitope  in 
domain 5  of ICAM-1. CA7 was expressed on soluble mo- 
nomeric  ICAM-1  but not dimeric soluble ICAM-1  dem- 
onstrating that it is monomer selective. The CA7 epitope is 
weakly  expressed  on  ceils  expressing  normal  transmem- 
brane  ICAM-1  compared with other ICAM-1  antibodies, 
suggesting that normal cell surface ICAM-1 is similar to the 
ICAM-1-HA homodimer. Interestingly, CA7 was strongly 
expressed on a glycolipid-anchored form of ICAM-1 and a 
domain  3-deleted form  of transmembrane  ICAM-1,  sug- 
gesting that these molecules are similar to soluble ICAM- 
1-HA  monomer.  Not  all  domain  5  antibodies  have  this 
property of being monomer selective, suggesting that CA7 
recognizes  a  unique  epitope.  CA7  expression  is  similarly 
low on  all cells expressing transmembrane  ICAM-1.  The 
CA7  epitope  is  likely to  recognize  a  region  involved  in 
ICAM-1 dimer contacts or surfaces made sterically inacces- 
sible by dimer formation. 
We  have  taken the first steps toward characterizing the 
structural basis of ICAM-1  dimerization and have targeted 
the  transmembrane  domain  and  domains  3-5  for  further 
study. Transmembrane domains play a critical role in oligo- 
merization of many membrane  proteins,  including glyco- 
phorin, the neu oncogene, and the T  cell antigen-receptor 
complex (45-47).  It is possible that the hemaggiutinin tag 
with  its alternating hydrophobic  and  hydrophilic residues 
effectively replaces the transmembrane domain of ICAM-1 
in organizing formation ofdimers by soluble ICAM-1-HA. 
The combined binding energies of the ectodomain interac- 
tions  mediating  ICAM-1  dimerization  appear  to  be  low 
based  on  the  failure  of conventional  soluble  ICAM-1  to 
form dimers.  ICAM-1  domain 3  appears to  contain a po- 
tential dimer contact region based on partial restoration of 
CA7  binding in  domain  3  deletion mutants  of ICAM-1. 
Domain  3  contains  a  hydrophobic  region  that  is  a  good 
candidate for a homophilic contact site in ICAM-1 dimers. 
The failure of ICAM-1 domains 1 and 2 plus an HA tag to 
form dimers suggests that these domains do not contain sig- 
nificant sites of interaction in dimer formation. However, it 
is intriguing that a  crystal structure  of domains  1 and 2  of 
the  related  Ig superfamily member  vascular cell  adhesion 
molecule (VCAM)-I shows a homodimeric unit cell (48). 
The efficiency of ICAM-1  cross-linking differed among 
BHK  cells stably  expressing human  ICAM-I,  COS  cells 
transiently expressing ICAM-1, and HUVEC  that naturally 
express high levels of ICAM-1  in response  to TNF  treat- 
ment  (40).  In  contrast,  CA7  binding does  not  indicate  a 
large  difference  in  the  level  of ICAM-1  oligomerization 
among  these  cell  types.  It  should  be  noted  that  even  in 
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ways possible to covalendy cross-hnk all pairs due to com- 
peting processes that consume reactive lysines before inter- 
molecular  bridges  are  formed.  However,  the  differences 
between  ICAM-1  on  different  cells suggest  that  there  are 
basic differences in the presentation of ICAM-1  or its con- 
formation at the surface between these cell types. The dif- 
ference  in  cross-linking efficiency may reflect a  difference 
in  access  of the  cross-linking  reagent  to  ICAM-1.  Some 
cells retain ICAM-1  in intracellular compartments (17) and 
it is possible that not all of the ICAM-1  detected by West- 
ern blotting in a specific cell type is at the surface.  Further- 
more,  HUVEC  display several ICAM-1  forms,  suggesting 
the  possibility  of ICAM-1  heterodimers  with  unknown 
polypeptides that may themselves cross-link with  different 
efficiencies. 
ICAM-1  interacts  with the  cytoskeleton through  its cy- 
toplasmic  tail  but  no  evidence  for  a  role  of cytoskeletal 
binding in ICAM-1  dimerization was found.  An ICAM-1 
cytoplasmic tail deletion  mutant was still dimeric based on 
lack of CA7  expression.  The  cytoplasmic tail  of ICAM-1 
binds ot-actinin (49). Since 0~-actinin is dimeric it may pro- 
mote ICAM-1  dimerization  (12).  Conversely,  the binding 
of a-actinin  to ICAM-1  cytoplasmic tails is weak at physi- 
ological ionic strength and may require ICAM-1  dimeriza- 
tion to allow bivalent binding (49). Thus,  ICAM-1  dimer- 
ization may be important for ICAM-1  interactions on both 
faces of the plasma membrane. 
ICAM-1  oligomerization  at  the  cell  surface  has  been 
suggested in other studies. ICAM-1 has been found to clus- 
ter in uropod structures  in T  and B  lymphoblasts  (17-19). 
This phenomenon  is related to cytoskeletal association (19) 
and  is  probably  a  higher  level  of organization  than  the 
ICAM-1  dimers described here. A  more recent study used 
fluorescence  resonance  energy  transfer with  bivalent  anti- 
bodies labeled with green and red dyes (21). Those authors 
interpreted their data to suggest that ICAM-1  is dimeric on 
some  cells and  not  on  others,  but we  feel  that  the  use  of 
bivalent antibodies in these experiments limits their resolu- 
tion to detecting clustering rather than molecular dimeriza- 
tion  which  would  require  monovalent  probes.  ICAM-1 
has also been  suggested  to associate with  the  multisubunit 
IL-2 receptor by resonance  energy transfer,  however,  it is 
unclear  whether  this  represents  association  of  ICAM-1 
dimers  with  the  IL-2  receptor  or  an  ICAM-1  monomer 
forming a heterooligomer with the  IL-2 receptor complex 
rather than another ICAM-1  monomer (20). 
ICAM-1  is also a ligand for the  neutrophil/macrophage 
integrin  Mac-1  (CDllb/CD18).  It  will  be  important  to 
determine  the  consequences  of ICAM-1  dimerization  for 
Mac-1  binding.  LFA-1  binds  to  domains  1  and  2  of 
ICAM-1 while Mac-1 binds to domain 3 of ICAM-1. Do- 
main 3  was implicated in dimerization  in this study so we 
tested  a  number  of domain  3  mutants  affecting  ICAM-1 
binding  to  Mac-1  (D229QP,./HLE,  R231/I,  N240DS/ 
KNA,  E254DE/KEK,  N269/D)  (50)  for  effects on  CA7 
epitope expression and did not find any change, suggesting 
that these mutants alter interaction  of ICAM-1  and Mac-1 
without  affecting  ICAM-1  dimerization  (Knorr,  R.,  and 
M. L. Dustin,  unpublished  observation). 
Clustering  of LFA-1  on activated lymphocytes has been 
suggested  as  a  prerequisite  for  LFA-l-mediated  adhesion 
(42).  Resting  lymphocytes  appear  to  lack  preclustered 
LFA-1 and therefore it has been suggested that they are not 
competent  for  LFA-l-mediated  adhesion  even  when 
acutely  activated  (51).  However,  it is clear that T  cell re- 
ceptor cross-linking can induce a dramatic increase in LFA- 
1--dependent  T  cell  adhesion  to  surfaces  bearing  purified 
ICAM-1 within minutes (30). We have found that purified 
ICAM-1  forms clusters  upon  reconstitution  and  this  clus- 
tering,  possibly  mimicking  cell  surface  dimerization,  may 
be a critical element in our ability to demonstrate adhesion 
of acutely activating resting T  cells to ICAM-1  substrates. 
Soluble  recombinant  ICAM-1  may not  adequately mimic 
cell  surface  dimers  when  adsorbed  to  plastic  in  a  mono- 
meric form and this may account for the failure of some in- 
vestigators  to  demonstrate  rapid  activation  of LFA-1  on 
resting  T  cells  for  binding  to  ICAM-1  (51).  Therefore, 
ICAM-1  homodimers  may  be  the  only  suitable  LFA-1 
ligand for acutely activated resting T  lymphocytes. 
The evidence that ICAM-1  is dimeric at the cell surface 
and that this dimerization leads to enhanced binding of pu- 
rified  LFA-1  and  cell  adhesion  is  timely  in  that  parallel 
studies  have demonstrated  three  distinct  ICAM-l-binding 
sites in LFA-I,  two in the  e~L subunit,  and one in  the  132 
subunit. All of these putative binding sites appear to include 
divalent  cation-binding  motifs  (52-55)  and  may  mediate 
coordination  of a critical oxygenated residue(s) in ICAM-1 
with metal ions held by two metal ion-dependent  adhesion 
site motifs in LFA-1, one in ceL and one in 132, and one EF 
hand-like  structure  in  c~L. ICAM  binding  to  LFA-1  may 
then  involve  convergence  of these  metal  ion  positioning 
motifs onto one ICAM or binding to two or three different 
ICAM  molecules.  In  the  latter  case  the  dimerization  of 
ICAM-1  would  offer a distinct  advantage in optimally po- 
sitioning  two  ICAM-1  molecules  for LFA-1  binding  and 
may account for the advantage ofdimeric ICAM-1 in initi- 
ating LFA-l-dependent  adhesion. 
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